Naturalistic, Retrospective Study on Clinical Experience of Ziprasidone in 3 University Hospitals.
- Author:
Seung Jae LEE
1
;
Do Hyung KANG
;
Kyung Sue HONG
;
Yeon Ho JOO
;
Nam Sick KIM
;
Jun Soo KWON
Author Information
1. Department of Psychiatry, Seoul National University College of Medicine, Seoul, Korea. kwonjs@plaza.snu.ac.kr
- Publication Type:Original Article
- Keywords:
Ziprasidone;
Efficacy;
Side effect;
Schizophrenia;
Other psychiatric disorder
- MeSH:
Antipsychotic Agents;
Diagnosis;
Diagnostic and Statistical Manual of Mental Disorders;
Electrocardiography;
Hospitals, University*;
Humans;
Retrospective Studies*;
Schizophrenia;
Weight Gain;
Weight Loss
- From:Journal of Korean Neuropsychiatric Association
2007;46(3):214-222
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: This naturalistic retrospective study investigated the effectiveness of ziprasidone measured by mean improvements of the Clinical Global Impression (CGI-I). Secondary objectives included prescribing patterns, tolerability and safety. METHODS: From May to July 2006, 98 psychiatric patients who have been taking ziprasidone for at least 2 weeks were selected. Their current clinical statuses were assessed by the interview and laboratory tests including electrocardiogram (ECG). Data on DSM-IV diagnoses, dosing, concomitant psychotropic medications, clinical changes, adverse effects, and laboratory findings were collected retrospectively. RESULTS: Ziprasidone was mostly prescribed for a switch from another antipsychotics for the treatment of schizophrenia. Two main reasons for a switch were unsatisfactory efficacy and poor tolerance, especially weight gain, of the preceding antipsychotic medication. Participants as a whole showed mean 2.7+/-1.0 of the CGI-Improvement. Significant weight reduction after switching to ziprasidone occurred, which was related to the clinical improvement. No significant increase of the QTc interval except one case was observed. CONCLUSION: The present study confirmed previous tolerability and safety data of ziprasidone as well as the results of its effectiveness.
